Valuation: Evolus, Inc.

Market Cap 530M 459M 430M 392M 738M 50.56B 750M 5.07B 1.98B 25.31B 1.99B 1.95B 84.42B P/E 2026 *
-17.2x
P/E 2027 * -45.8x
Enterprise Value 657M 569M 534M 487M 916M 62.68B 930M 6.28B 2.45B 31.37B 2.47B 2.41B 105B EV / Sales 2026 *
1.97x
EV / Sales 2027 * 1.69x
Free-Float
83.41%
Yield 2026 *
-
Yield 2027 * -
1 day-1.23%
1 week+8.23%
Current month+37.33%
1 month+23.01%
3 months+19.35%
6 months+86.51%
Current year+20.60%
1 week 7.18
Extreme 7.18
8.43
1 month 5.44
Extreme 5.445
8.43
Current year 3.86
Extreme 3.86
8.43
1 year 3.86
Extreme 3.86
8.43
3 years 3.86
Extreme 3.86
17.82
5 years 3.86
Extreme 3.86
17.82
10 years 2.85
Extreme 2.85
39.5
Manager TitleAgeSince
Chief Executive Officer 48 2018-05-05
Director of Finance/CFO 48 2025-09-07
Chief Operating Officer - 2022-08-31
Director TitleAgeSince
Chairman 63 2017-12-31
Director/Board Member 71 2018-02-11
Director/Board Member 48 2018-05-05
Date Insider Type Main position Quantity % Market Cap.
3/16/26 Fiscal year

Chief Executive Officer

251,698 0.3891%
2/17/26 Free

Chief Financial Officer

420,449 0.6500%
2/17/26 Free

Chief Technology Officer

328,475 0.5078%
Change 5-day change 1-year change 3-year change Capi.($)
-1.23%+8.23%+23.20%-18.58% 536M
-0.92%+1.43%+83.05%+128.86% 1,088B
+0.47%+1.98%+50.26%+50.75% 629B
+0.83%+2.85%+24.49%+64.82% 440B
-0.88%-0.66%+45.09%+36.64% 359B
-0.37%-1.15%+26.89%+36.31% 291B
+0.05%-1.20%+2.31%+6.15% 245B
+0.40%+3.21%+44.42%+59.17% 225B
-0.42%+1.58%-8.48%-51.94% 204B
+1.67%+5.56%+14.98%+72.68% 168B
Average -0.04%+2.31%+30.62%+38.48% 364.97B
Weighted average by Cap. -0.13%+1.47%+46.05%+65.95%

Financials

2026 *2027 *
Net sales 333M 289M 271M 247M 465M 31.83B 472M 3.19B 1.25B 15.93B 1.25B 1.22B 53.15B 391M 339M 318M 290M 545M 37.33B 554M 3.74B 1.46B 18.69B 1.47B 1.44B 62.34B
Net income -34.96M -30.3M -28.41M -25.9M -48.74M -3.34B -49.52M -334M -131M -1.67B -131M -128M -5.57B -11.98M -10.38M -9.73M -8.87M -16.7M -1.14B -16.97M -115M -44.74M -572M -44.97M -44M -1.91B
Net Debt 127M 110M 103M 94.09M 177M 12.12B 180M 1.22B 474M 6.07B 477M 466M 20.24B 132M 114M 107M 97.8M 184M 12.6B 187M 1.26B 493M 6.31B 496M 485M 21.04B
Logo Evolus, Inc.
Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.
Employees
353
Date Price Change Volume
26-08-13 US$8.020 -1.23% 778,366
26-08-12 US$8.120 -2.64% 959,131
26-08-11 US$8.340 +10.17% 2,794,708
26-08-10 US$7.570 -0.26% 1,395,570
26-08-07 US$7.590 +2.43% 1,631,994
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
8.020USD
Average target price
14.67USD
Spread / Average Target
+82.88%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. EOLS Stock